Pappas Capital LLC
01/08/2009 | Press release | Archived content
Plexxikon and Roche enter second partnership
News | 01. 08. 2009
Plexxikon
Berkeley, CA and Basel, Switzerland - January 8, 2009 -- Plexxikon Inc. and Roche (SWX:ROG), today announced that they have entered into an agreement to develop and commercialize a second novel kinase inhibitor, PLX5568. The main focus of this partnership will be the development of this small molecule inhibitor of Raf kinase as an oral therapeutic treatment for polycystic kidney disease (PKD). There is currently no registered treatment for PKD which affects over 600,000 patients in the U.S and is the most common life- threatening genetic disease.
Pappas Capital LLC published this content on January 08, 2009, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]